Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the ...

Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: ...

Takeda reported an earnings per share (EPS) of -$0.23, missing the estimated EPS of -$0.03, indicating challenges in meeting ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.